

## Stereoselective Synthesis of Polyoxamic Acid from (*R*)-Phenylglycine #

G. Veeresa and Apurba Datta\*


Organic III, Indian Institute of Chemical Technology, Hyderabad - 500 007, India

Received 8 September 1997; revised 23 October 1997; accepted 24 October 1997

**Abstract** : An efficient route for the synthesis of the biologically important amino acid, polyoxamic acid (**1**) has been developed via a *syn* selective Grignard reaction of vinylmagnesium bromide on (*R*)-*N*-Boc-phenylglycinal and utilization of the phenyl group as a masked carboxyl synthon.

© 1997 Elsevier Science Ltd. All rights reserved.


The 1,2-amino alcohol fragment is found in many natural products, in particular as a central moiety of non-proteinogenic amino acids and amino polyols. An important example of the above class of compounds is polyoxamic acid (**1**), component amino acid of the polyoxin group of nucleoside antibiotics.<sup>1</sup> As a consequence of the potent biological activity associated with these compounds<sup>2</sup>, a variety of chemical syntheses of polyoxamic acid have been developed over the past several years.<sup>3</sup> However, considering the biological importance of **1** and related compounds, development of new methods for synthesizing this amino acid still remains challenging and worthwhile. Thus, in continuation of our studies on the synthesis of non-proteinogenic hydroxy amino acids of pharmaceutical interest<sup>4</sup> we decided to investigate the synthesis of polyoxamic acid starting from commercially available (*R*)-phenylglycine (**3**). It has been shown that chelation controlled addition of Grignard reagents to *N*-Boc- $\alpha$ -amino aldehydes results in the formation of the corresponding 1,2-amino alcohols with good *syn* diastereoselection.<sup>4b,5,6</sup> Accordingly, the key features of our proposed synthesis involve i) *syn* selective addition of vinylmagnesium bromide to (*R*)-phenylglycinal, affording the amino alcohol **2** (Scheme 1) with required stereochemistry, and ii) utilization of the phenyl group as a carboxylic acid synthon and the vinyl group as a precursor for the *vicinal* diol. The results of the studies are described herein.



Scheme 1

*N*-Boc-phenylglycinol (**4**) was prepared in a one-pot reaction by lithium aluminium hydride reduction and derivatization of (*R*)-phenylglycine (**3**, Scheme 2). Swern oxidation of **4** followed by *in-situ* reaction of the resulting aldehyde with vinylmagnesium bromide yielded the corresponding allylic alcohol **2** with good


diastereoselection (9:1, diastereoisomers separated by column chromatography) in favour of the *syn* isomer, which is in accordance with the earlier reported observation.<sup>6</sup> The pivotal intermediate **2** with the required *syn*- $\beta$ -amino alcohol framework and two differential functional groups in phenyl and the terminal olefin thus represents a convenient launching pad for the proposed synthesis.



a. LAH, THF then  $\text{Boc}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ . b. Swern oxidation then  $\text{H}_2\text{C}=\text{CHMgBr}$ , THF. c.  $\text{Me}_2\text{C}(\text{OMe})_2$ , PPTS, toluene. d. AD-mix- $\beta$ . e. TBDMSCl, imidazole, DMAP,  $\text{CH}_2\text{Cl}_2$ . f. i)  $\text{Ph}_3\text{P}$ ,  $\text{EtO}_2\text{CN}:\text{NCO}_2\text{Et}$ , 4-nitrobenzoic acid, THF. ii)  $\text{K}_2\text{CO}_3$ , MeOH.

**Scheme 2**

Acetonide protection of the amino alcohol functionality of **2** afforded the vinyl oxazolidinone **5** (Scheme 2) and the assigned stereochemistry was further verified by NMR studies where the observed coupling constant ( $J = 8.3$  Hz) between the two protons in the oxazolidinone ring ( $\text{C}_4\text{-C}_5$ ) is indicative of a *trans* relationship. Attempted dihydroxylation of the terminal double bond of **5** using AD-mix- $\beta$  resulted in an inseparable mixture of alcohols **6**. However, treatment of this mixture with TBDMSCl under standard conditions gave the mono-silylated derivatives **7** and **8** in nearly quantitative yield, which were separated by column chromatography. The poor diastereoselectivity (3:2) in favour of the  $\beta$ -alcohol during dihydroxylation is not very surprising as the chiral olefin and the catalyst represents a mismatched pair. In a separate experiment, oxidation of the alcohol **7** to the corresponding ketone **9** (Scheme 3) followed by reduction of the




a. 2-Iodoxybenzoic acid, DMSO, THF. b.  $\text{Zn}(\text{BH}_4)_2$ , THF.

**Scheme 3**

resulting carbonyl group with  $\text{Zn}(\text{BH}_4)_2$  (*erythro* selective)<sup>7</sup> under standard conditions provided the *anti*-alcohol **8** as the major isomer (>90%), which was found to be similar in all respects to the alcohol **8** as obtained previously (Scheme 2), thereby confirming the stereochemical assignment of the alcohols **7** and **8**. The undesired isomer **8** was next converted to the required  $\beta$ -hydroxy compound **7** via a Mitsunobu protocol

as shown in Scheme 2.

After a few unsuccessful trials, we could find the right combination of reaction sequence and protecting groups for converting the protected amino triol **7** to the target molecule in good overall yield, as depicted in scheme 4. Thus, deprotection of the silylether linkage of **7** and subsequent acetylation of the diol yielded the diacetate **10**. N,O-deprotection of the acetonide linkage followed by acetylation of the resulting hydroxy group formed the *N*-Boc protected triacetate **11**. Finally, degradative oxidation of the phenyl group yielded the corresponding carboxylic acid **12a**, suitably protected for further peptide coupling towards the syntheses of various polyoxins. Also, conversion of the acid **12a** to its *tert*-butyl ester **12b** afforded a known precursor<sup>8</sup> of polyoxamic acid thereby completing a formal synthesis of **1**.<sup>9</sup>



a.  $\text{Bu}_4\text{NF}$ , THF. b.  $\text{Ac}_2\text{O}$ , DMAP, py. c. 80%  $\text{AcOH}$ , 50°C. d.  $\text{RuCl}_3 \cdot \text{H}_2\text{O}$ ,  $\text{NaIO}_4$ ,  $\text{CCl}_4$ ,  $\text{CH}_3\text{CN}$ ,  $\text{H}_2\text{O}$ . e.  $\text{Me}_2\text{C}=\text{CH}_2$ ,  $\text{BF}_3 \cdot \text{Et}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ .

**Scheme 4**

In conclusion, the above method represents a practical and relatively short synthesis of polyoxamic acid and offers a viable alternative to the existing methods for synthesizing the title compound and its analogs.

**Acknowledgments** : We thank Dr. M. K. Gurjar for his support and encouragement. GV also thanks CSIR, New Delhi for a research fellowship (SRF).

### References and Notes

- # IICT communication No. 3892
1. (a) Suzuki, S.; Isono, K.; Nagatsu, J.; Mizutani, T.; Kawashima, Y.; Mizuno, T. *J. Antibiot.* **1965**, *A18*, 131. (b) Isono, K. *J. Antibiot.* **1988**, *41*, 1711-1739. (c) Isono, K. *Pharm. Ther.* **1991**, *52*, 269.
2. Cooper, A.B.; Desai, J.; Lovey, R.G.; Saksena, A.K.; Girijavallabhan, V.M.; Ganguly, A.K.; Loebenberg, D.; Parmegiani, R.; Cacciapuoti, A. *Bioorg. Med. Chem. Lett.* **1993**, *3*, 1079-1084 and references therein.
3. For a review, see Casiraghi, G.; Zanardi, F.; Rasso, G.; Spanu, P. *Chem. Rev.* **1995**, *95*, 1677-1716. For some recent examples see (a) Palomo, C.; Oiarbide, M.; Esnal, A. *Chem. Commun.* **1997**, 691-692. (b) Kang, S.H.; Choi, H-W. *Chem. Commun.* **1996**, 1521-1522 and references cited therein.
4. (a) Ravi Kumar, J. S.; Datta, A. *Tetrahedron Lett.* **1997**, *38*, 473-476. (b) Veerasha, G.; Datta, A. *Tetrahedron Lett.* **1997**, *38*, 5223-5224.

5. a) Jayasinghe, L.R.; Datta, A.; Ali, S.M.; Zygmunt, J.; Vander Velde, D.G.; Georg, G.I. *J. Med. Chem.* **1994**, *37*, 2981-2984. b) Ali, S.M.; Hoemann, M.Z.; Aube, J.; Mitscher, L.A.; Georg, G.I.; McCall, R.; Jayasinghe, L.R. *J. Med. Chem.* **1995**, *38*, 3821-3828.
6. Denis, J-N.; Correa, A.; Greene, A.E. *J. Org. Chem.* **1991**, *56*, 6939-6942.
7. For a recent example see : (a) Doi, Y.; Ishibashi, M.; Kobayashi, J. *Tetrahedron*, **1996**, *52*, 4573-4580. For a review see : (b) Oishi, T.; Nakata, T. *Acc. Chem. Res.* **1984**, *17*, 338-344.
8. Matsuura, F.; Hamada, Y.; Shiori, T. *Tetrahedron Lett.* **1994**, *35*, 733-736.
9. All the compounds synthesized were fully characterized by IR,  $^1\text{H}$  and  $^{13}\text{C}$  NMR and mass spectral data. Characteristic data for some key compounds are given below:
- 5**: light yellow viscous liquid;  $[\alpha]_{\text{D}} = -32.7$  ( $c=1.4$ ,  $\text{CHCl}_3$ ); IR (neat)  $1696\text{ cm}^{-1}$ ;  $^1\text{HNMR}$  (400 MHz,  $\text{CDCl}_3$ )  $\delta$  1.03 (s, 9H, tBu), 1.72 and 1.74 (2s, 6H,  $2\times\text{CH}_3$ ), 4.25 (br t,  $J=7.5$  Hz, 1H, H-5), 4.36 (br d,  $J=6.9$  Hz, 1H, H-4), 5.19 (m, 2H,  $\text{CH}_2=\text{CH}-$ ), 5.87 (m, 1H,  $-\text{CH}-\text{CH}_2-$ ), 7.32 (m, 5H, Ph); CIMS 304 (MH $^+$ ).
- 7**: light yellow viscous liquid;  $[\alpha]_{\text{D}} = -21.2$  ( $c=1.3$ ,  $\text{CHCl}_3$ ); IR (neat)  $3376$ ,  $1696\text{ cm}^{-1}$ ;  $^1\text{HNMR}$  (200 MHz,  $\text{CDCl}_3$ )  $\delta$  0.05 and 0.06 (2 s, 6H,  $\text{tBuSiMe}_2$ ), 0.85 (s, 9H,  $\text{tBuSiMe}_2$ ), 1.1 (br s, 9H, tBuO), 1.65 and 1.72 (2s, 6H,  $-\text{C}(\text{Me})_2$ ), 2.32 (br s, 1H, OH, exchangeable with  $\text{D}_2\text{O}$ ), 3.65 (m, 3H), 3.89 (br t,  $J=7.1$  Hz, 1H), 4.85 (br s, 1H, Ph-CH), 7.26 (m, 5H, Ph); MS (FAB $^+$ ) 452 (MH $^+$ ).
- 11**: colourless liquid;  $[\alpha]_{\text{D}} = +12.9$  ( $c=0.6$ ,  $\text{CHCl}_3$ ); IR (neat)  $3410$ ,  $1746$ ,  $1711$  (br)  $\text{cm}^{-1}$ ;  $^1\text{HNMR}$  (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.4 (br s, 9H, tBu), 2.05 (s, 3H, OAc), 2.1 (s, 3H, OAc), 2.15 (s, 3H, OAc), 4.05 (dd,  $J=4.5$  and  $11.4$  Hz, 1H,  $\text{CH}_2\text{OAc}$ ), 4.26 (br d,  $J=11.1$  Hz, 1H,  $\text{CH}_2\text{OAc}$ ), 5.1 (m, 3H), 5.45 (br d,  $J=9.0$  Hz, 1H, NH), 7.3 (m, 5H, Ph); CIMS 424 (MH $^+$ ).
- 12a**: colourless liquid;  $[\alpha]_{\text{D}} = 22.2$  ( $c=1.5$ ,  $\text{CHCl}_3$ ); IR (neat)  $3360$ ,  $1754$ ,  $1726$  (br)  $\text{cm}^{-1}$ ;  $^1\text{HNMR}$  (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.4 (s, 9H, tBu), 2.04 (s, 6H,  $2\times\text{OAc}$ ), 2.13 (s, 3H, OAc), 4.11 (dd,  $J=4.5$  and  $11.2$  Hz, 1H,  $\text{CH}_2\text{OAc}$ ), 4.29 (br d,  $J=11.4$  Hz, 1H,  $\text{CH}_2\text{OAc}$ ), 4.77 (br d,  $J=9.4$  Hz, 1H,  $\text{CHOAc}$ ), 4.89 (br s, 1H,  $\text{CO}_2\text{H}$ ), 5.08 (m, 1H,  $\text{CHOAc}$ ), 5.17 (br d,  $J=9.5$  Hz, 1H,  $\text{CH}-\text{CO}_2\text{H}$ ), 5.65 (br d,  $J=9.2$  Hz, 1H, NH);  $^{13}\text{CNMR}$  (50 MHz,  $\text{CDCl}_3$ )  $\delta$  172.8, 170.8, 169.7, 169.4, 155.4, 80.8, 77.2, 70.2, 68.1, 61.7, 30.8, 29.6, 28.2, 20.8, 20.6, 20.4; CIMS: 392 (MH $^+$ ).
- 12b**: colourless liquid;  $[\alpha]_{\text{D}} = 15.6$  ( $c=0.6$ ,  $\text{CHCl}_3$ ) [lit 7.  $[\alpha]_{\text{D}} = 14.1$  ( $c=1.12$ ,  $\text{CHCl}_3$ )] IR (neat)  $3350$ ,  $1748$ ,  $1690\text{ cm}^{-1}$ ;  $^1\text{HNMR}$  (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.49 (br s, 18H,  $2\times\text{tBu}$ ), 2.05 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.16 (s, 3H, OAc), 4.20 (br d,  $J=3.2$  Hz, 2H,  $\text{CH}_2\text{OAc}$ ), 4.97 (br d,  $J=8.8$  Hz, 2H,  $2\times\text{CHOAc}$ ), 5.41 (br d,  $J=8.9$  Hz, 1H,  $\text{CH}-\text{CO}_2\text{Bu}^t$ ), 6.01 (d,  $J=9.8$  Hz, 1H, NH). CIMS 448 (MH $^+$ ).